Download PDF
Der Nuklearmediziner 2003; 26(2): 92-96
DOI: 10.1055/s-2003-41800
Gastrointestinale Diagnostik

© Georg Thieme Verlag Stuttgart · New York

Nuklearmedizinische Diagnostik von Raumforderungen der Leber

Diagnosis of Liver Lesions in Nuclear MedicineT. Krause1 , F. Jüngling1
  • 1Abteilung für Nuklearmedizin · Universität Bern · Inselspital
Further Information

Publication History

Publication Date:
08 September 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Bedeutung der konventionellen nuklearmedizinischen Diagnostik von Raumforderungen der Leber hat mit der Entwicklung neuer Bildgebungsprotokolle in der Sonographie, Computertomographie (CT) und Magnetresonanz-Tomographie (MRT) eine deutliche Wandlung erfahren. Mit der Positronen-Emissions-Tomographie (PET) steht ein Verfahren zur Verfügung, welches eine gewebe- und funktionsspezifische Charakterisierung in Ergänzung zu den modernen, morphologischen Verfahren erlaubt und somit prinzipiell zur Dignitätsbeurteilung bekannter Leberläsionen geeignet ist. Die vorliegende Übersicht beschreibt den gegenwärtigen Stellenwert der nuklearmedizinischen Diagnostik inklusive PET für die Diagnostik fokaler Leberläsionen unter besonderer Berücksichtigung der klinischen Anwendung verschiedener Untersuchungsverfahren im klinischen Kontext.

Abstract

With the introduction of new imaging protocols for ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), the importance of conventional nuclear medicine diagnostic procedures has changed fundamentally. With the introduction of positron emission tomography (PET) into routine diagnostics, the assessment of tissue-specific function adds on to the modern, morphological imaging procedures and in principle allows for differentiating benign from malignant lesions. The actual clinical value of nuclear medicine procedures for the diagnostic workup of focal liver lesions is discussed.

Schlüsselwörter

Leberrundherd - kavernöses Hämangiom - FNH - HCC - Lebermetastase

Key words

Liver Lesions - Cavernous Hemangioma - FNH - HCC - Liver Metastasis

Literatur

  • 1 Bonanno N, Baldari S, Cerrito A, Zimbaro G, Restifo G, Blandino A, Freni O. Diagnosis of hepatic hemangiomas with 99mTc-labeled red blood cell scanning: value of SPECT.  J Nucl Biol Med. 1991;  35 135-140
    PubMedGoogle Scholar
  • 2 Brant W E, Floyd J L, Jackson D E, Gilliland J D. The radiological evaluation of hepatic cavernous hemangioma.  Jama. 1987;  257 2471-2474
    CrossrefPubMedGoogle Scholar
  • 3 Calvet X, Pons F, Bruix J, Bru C, Lomena F, Herranz R, Brugera M, Faus R, Rodes J. Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma: relationship between detectability and tumor differentiation.  J Nucl Med. 1988;  29 1916-1920
    PubMedGoogle Scholar
  • 4 Diederichs C G, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs H J, Beger H G, Reske S N. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.  Pancreas. 2000;  20 109-116
    PubMedGoogle Scholar
  • 5 Dose J, Bleckmann C, Bachmann S, Bohuslavizki K H, Berger J, Jenicke L, Habermann C R, Janicke F. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients.  Nucl Med Commun. 2002;  23 857-864
    CrossrefPubMedGoogle Scholar
  • 6 el-Desouki M, Mohamadiyeh M, al-Rashed R, Othman S, al-Mofleh I. Features of hepatic cavernous hemangioma on planar and SPECT Tc-99m-labeled red blood cell scintigraphy.  Clin Nucl Med. 1999;  24 583-589
    CrossrefPubMedGoogle Scholar
  • 7 Ginsberg F, Slavin J D, Jr., Spencer R P. Hepatic angiosarcoma: mimicking of angioma on three-phase technetium-99m red blood cell scintigraphy.  J Nucl Med. 1986;  27 1861-1863
    PubMedGoogle Scholar
  • 8 Ho C L, Yu S C, Yeung D W. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.  J Nucl Med. 2003;  44 213-221
    PubMedGoogle Scholar
  • 9 Huebner R H, Park K C, Shepherd J E, Schwimmer J, Czernin J, Phelps M E, Gambhir S S. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.  J Nucl Med. 2000;  41 1177-1189
    PubMedGoogle Scholar
  • 10 Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, Kawabe J, Ochi H. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors.  Ann Nucl Med. 2000;  14 121-126
    PubMedGoogle Scholar
  • 11 Ji E K, Ryu J S, Kang G H, Moon D H, Auh Y H, Lee H K. Pelioid-type hepatocellular carcinoma masquerading as a hepatic hemangioma on technetium-99m red blood cell scintigraphy.  Clin Nucl Med. 2001;  26 33-35
    PubMedGoogle Scholar
  • 12 Karhunen P J. Benign hepatic tumours and tumour like conditions in men.  J Clin Pathol. 1986;  39 183-188
    Google Scholar
  • 13 Khan M A, Combs C S, Brunt E M, Lowe V J, Wolverson M K, Solomon H, Collins B T, Di Bisceglie A M. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.  J Hepatol. 2000;  32 792-797
    CrossrefPubMedGoogle Scholar
  • 14 Kinkel K, Lu Y, Both M, Warren R S, Thoeni R F. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.  Radiology. 2002;  224 748-756
    CrossrefPubMedGoogle Scholar
  • 15 Kotzerke J, Schwarzrock R, Krischek O, Wiese H, Hundeshagen H. Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma, adenoma, and focal nodular hyperplasia.  J Nucl Med. 1989;  30 1278-1279
    PubMedGoogle Scholar
  • 16 Krause T, Hauenstein K, Studier-Fischer B, Schuemichen C, Moser E. Improved evaluation of technetium-99m-red blood cell SPECT in hemangioma of the liver.  J Nucl Med. 1993;  34 375-380
    PubMedGoogle Scholar
  • 17 Krug B, Dietlein M, Groth W, Stutzer H, Psaras T, Gossmann A, Scheidhauer K, Schicha H, Lackner K. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.  Acta Radiol. 2000;  41 446-452
    CrossrefPubMedGoogle Scholar
  • 18 Langenhoff B S, Oyen W J, Jager G J, Strijk S P, Wobbes T, Corstens F H, Ruers T J. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.  J Clin Oncol. 2002;  20 4453-4458
    CrossrefPubMedGoogle Scholar
  • 19 Lubbers P R, Ros P R, Goodman Z D, Ishak K G. Accumulation of technetium-99m sulfur colloid by hepatocellular adenoma: scintigraphic- pathologic correlation.  AJR Am J Roentgenol. 1987;  148 1105-1108
    PubMedGoogle Scholar
  • 20 Middleton M L. Scintigraphic evaluation of hepatic mass lesions: emphasis on hemangioma detection.  Semin Nucl Med. 1996;  26 4-15
    PubMedGoogle Scholar
  • 21 Osman M M, Cohade C, Nakamoto Y, Marshall L T, Leal J P, Wahl R L. Clinically Significant Inaccurate Localization of Lesions with PET/CT: Frequency in 300 Patients.  J Nucl Med. 2003;  44 240-243
    PubMedGoogle Scholar
  • 22 Rabinowitz S A, McKusick K A, Strauss H W. 99mTc red blood cell scintigraphy in evaluating focal liver lesions.  AJR Am J Roentgenol. 1984;  143 63-68
    PubMedGoogle Scholar
  • 23 Rogers J V, Mack L A, Freeny P C, Johnson M L, Sones P J. Hepatic focal nodular hyperplasia: angiography, CT, sonography, and scintigraphy.  AJR Am J Roentgenol. 1981;  137 983-990
    PubMedGoogle Scholar
  • 24 Rostom A Y, Powe J, Kandil A, Ezzat A, Bakheet S, el-Khwsky F, el-Hussainy G, Sorbris R, Sjoklint O. Positron emission tomography in breast cancer: a clinicopathological correlation of results.  Br J Radiol. 1999;  72 1064-1068
    PubMedGoogle Scholar
  • 25 Schild H, Kreitner K F, Thelen M, Gronninger J, Weber M, Borner N, Storkel J, Eissner D. [Focal nodular hyperplasia of the liver in 930 patients].  ROFO Fortschr Geb Rontgenstr Nuklearmed. 1987;  147 612-618
    PubMedGoogle Scholar
  • 26 Shih W J, Lee J K, Mitchell B. False-positive results for hepatic hemangioma on Tc-99m RBC SPECT caused by a liver metastasis from small-cell lung carcinoma.  Clin Nucl Med. 1996;  21 898-899
    CrossrefPubMedGoogle Scholar
  • 27 Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S, Ochi H. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.  Am J Gastroenterol. 2001;  96 1877-1880
    CrossrefPubMedGoogle Scholar
  • 28 Teefey S A, Hildeboldt C C, Dehdashti F, Siegel B A, Peters M G, Heiken J P, Brown J J, McFarland E G, Middleton W D, Balfe D M, Ritter J H. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET.  Radiology. 2003;  226 533-542
    CrossrefPubMedGoogle Scholar
  • 29 Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.  J Nucl Med. 1994;  35 1965-1969
    PubMedGoogle Scholar
  • 30 Trojan J, Schroeder O, Raedle J, Baum R P, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.  Am J Gastroenterol. 1999;  94 3314-3319
    CrossrefPubMedGoogle Scholar
  • 31 Wester H J, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau F C, Reubi J C, Schwaiger M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide.  Eur J Nucl Med Mol Imaging. 2003;  30 117-122
    CrossrefPubMedGoogle Scholar
  • 32 Ziessman H A, Silverman P M, Patterson J, Harkness B, Fahey F H, Zeman R K, Keyes J W Jr. Improved detection of small cavernous hemangiomas of the liver with high-resolution three-headed SPECT.  J Nucl Med. 1991;  32 2086-2091
    PubMedGoogle Scholar

Prof. Dr. Thomas Krause

Abteilung für Nuklearmedizin · Universität Bern · Inselspital

CH 3010 Bern

Phone: +41/31/6 32 26 10

Email: thomas.krause@insel.ch

      >